If you are working on malaria in East or Southern Africa you are invited to participate in the survey of the Embassy of Switzerland to Tanzania and Zambia.*
Cyclone Idai Causes ‘Spike’ in Malaria Cases
By Thomas Locke
Cyclone Idai causes ‘spike’ in malaria cases, Oxford Uni researchers head to Africa to sequence mosquito DNA and the NothingButNets Leader Summit takes place in the US capitol.
Listen to this podcast
The University of Malaya hosted the "Current Tools to Combat Malaria - with Special Focus on Plasmodium knowlesi" workshop on March 4 - 8, 2019, which had 20 participants from eight different countries. Dr Lucas Low Van Lun covered this intensive week of lectures and practical sessions and reported the daily lessons learnt in a series of reports posted in the Resource Hub.
The Guidelines for malaria vector control provide a “one-stop shop” for all countries and partners working to implement effective malaria vector control measures. They cover the 2 core malaria vector control interventions – ITNs and IRS – as well as supplementary interventions, namely chemical and biological larvicides, and personal protection measures, such as the use of topical repellents.
Geneva – Paris, 25 February 2019 Today the RBM Partnership to End Malaria announced that Paris, France, will be the official host city of World Malaria Day 2019 on 25th April.
This report has been prepared to provide a comprehensive account of the history of malaria and its control in the Islamic Republic of Iran for specialists and lay readers alike. It is based on published and unpublished reports, especially from the Ministry of Health and Medical Education, Tehran, and from the World Health Organization. The main findings are summarized below.
Attention is drawn to the following three publications that are relevant to the preparation of manuscripts on malaria:
Markus, M.B. 2019. Plasmodium – Yet More Don’ts. Trends in Parasitology 35 (2): 101–102.
McFadden, G.I. 2019. Plasmodium – More Don’ts. Trends in Parasitology 35 (1): 4–6.
An article on vivax malarial recurrences was highlighted in the "Global Malaria News" section of last week's MalariaWorld Newsletter. Below (in the next paragraph) is a relevant explanation concerning the article (http://theconversation.com/why-does-malaria-recur-how-pieces-of-the-puzz...):
WHO is undertaking a consultative process to solicit inputs into a prioritization framework for the research and development (R&D) of malaria health products. A draft report “Analysis of Malaria R&D Priorities” identifies five key challenges that represent threats or barriers to achieving the WHO Global Technical Strategy for Malaria 2016–2030 goals. This early copy of the report is being shared at a time when WHO is exploring how best to guide and support the development of priority solutions to meet public health needs.
WHO welcomes feedback on this draft report until 28 February 2019, including the correction of errors or omissions, updates to product development pipelines, and perspectives on the approach to prioritization.
FRANCE 24 brings you an in-depth investigation into the debate between those for and against this natural anti-malaria remedy, which appears as a threat to large pharmaceutical laboratories.
MESA co-hosting a critical global gathering in response to the latest disease reality and future innovation and financing needs
The MESA Alliance is set to co-host an invite-only scientific symposium entitled, “Innovate for Collective Impact to End Malaria”, on Friday, January 11, 2019, at the National Academy of Sciences in Washington, DC, USA. Its core objective is to frame a response to the 2018 World Malaria Report and to develop innovative approaches to collectively bridge critical issues in malaria eradication spanning research, financing, and implementation.
We are proud to inform you that MalariaWorld's Bart Knols has won the Marc Cornelissen Brightlands Award 2018 for his work in the fight against malaria.
Malaria is on the rise in more than 13 countries. And that is very scary!
This year's report shows that after an unprecedented period of success in global malaria control, progress has stalled. Data from 2015–2017 highlight that no significant progress in reducing global malaria cases was made in this period. There were an estimated 219 million cases and 435 000 related deaths in 2017.
The World malaria report 2018 draws on data from 91 countries and areas with ongoing malaria transmission. The information is supplemented by data from national household surveys and databases held by other organizations.
The most promising or the most frightening experiment in the fight against malaria: should or shouldn’t we use genetically modified mosquitoes to combat malaria?
TEXAS BIOMEDICAL RESEARCH INSTITUTE - PUBLIC RELEASE: 17-OCT-2018
More than 150 people have died from Ebola virus disease in 2018
San Antonio, Texas (October 17, 2018) -- Ebola virus is a continuing threat in Central and West Africa, with an outbreak currently taking place in the Democratic Republic of Congo. The disease kills up to 90% of the people who get infected, and more than 150 people have died from Ebola so far this year. The factors that determine who is susceptible to Ebola infection and who is not are still a mystery.
Silas Majambere, Mosquito Consulting
The amount of time that passes between a symptomatic vivax malarial episode and a subsequent recurrence has in the past often been regarded as an indication as to whether the recurrence is a relapse (hypnozoite origin) or a recrudescence (merozoite origin). It should be noted that in the light of new knowledge and understanding, the time factor is not a valid criterion. (Link to first paper). (Link to second paper).
This repository comprises a carefully selected set of more than 190,000 bibliographic records covering all aspects of research on malaria.
- Pilot trial shows suppository form of artesunate can slash severe malaria deaths
- Success down to drug formulation, better knowledge of disease also reported
- Large-scale rollout in well-functioning health systems could be ‘ground-breaking’
The French periodical PARIS MATCH published an extensive document on the fight against malaria with Artemisia annua and Artemisia afra. And the dubious role WHO plays.
We talk about asymptomatic, submicroscopic plasmodial infections as potentially being a threat to the elimination of malaria. This is, of course, partly because such infections are not normally treated; especially not in rural endemic areas where laboratory facilities are limited. An aggravation of the situation is when parasitaemias are so low that they cannot be detected by molecular diagnosis (where available) either. But obstacles to elimination are probably even greater than has been realized.
Progress in malaria elimination across the Asia-Pacific is at critical cross-roads, threatened by the spread of multidrug resistant falciparum malaria and continued transmission among marginalized and mobile populations living and working in conditions beyond the reach of traditional malaria control interventions.
As you probably do, I eagerly check MalariaWorld almost every day, and when I have something to contribute, post a blog or comment. But I am disappointed by the lack of responses to my contributions, or to those from all of you. How can we improve this?
Since almost 10,000 people are connected thru MalariaWorld, we might make real progress if we can all contribute. I want to end malaria sooner, not later. Do you agree?
Amiodarone which is used to control irregular heartbeat also has a protective effect in malaria. It triggers eryptosis and the clearance of malaria infected erythrocytes. In Plasmodium berghei infected mice amiodarone injections increased the survival. It is interesting to note that amiodarone is also active against other tropical diseases like Chagas or Leishmaniasis, both in vitro and in vivo, probably by disrupting the parasites' Ca(2+) homeostasis,
It is valuable and refreshing to see contributions to strategies for malaria suppression in Africa from other disciplines, such as economics. Killeen and Reed pointed out that the portfolio effect cushions mosquito populations and malaria transmission against vector control interventions.(Killeen GF, Reed TE. Malar J. 2018 Aug 10;17(1):291. doi: 10.1186/s12936-018-2441-z.) Thus it must be considered when planning a strategy for Africa.
Vaccines blocking the invasion of malaria sporozoites failed so far, after 30 years of efforts, millions spent, and disastrous human clinical trials. The efforts and the millions are now focused on vaccines blocking transmission by gametocytes. The results are not yet encouraging but the updated Malaria Vaccine Technology Roadmap foresees that there will be a TBV vaccine available in 2030. The update was necessary as the program launched by WHO in 2000 ( TDR/RBM/MAL/VAC/2000.1) has not yet progressed very far.